VEC-5
| Code | Size | Price |
|---|
| TAR-T26316-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26316-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26316-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
VEC-5 is a HIV-1 inhibitor. VEC5 have been evaluated for their inhibitory potential employing ligand receptor and protein-protein interactions studies. VEC-5 exhibited better interaction with Vif than RN18.
CAS:
374679-27-3
Formula:
C29H21NO4
Molecular Weight:
447.49
Purity:
0.98
SMILES:
CCOC(=O)c1cc(C(=O)c2ccc3ccccc3c2)n2ccc(cc12)C(=O)c1ccccc1
References
1. Sinha C, Nischal A, Bandaru S, Kasera P, Rajput A, Nayarisseri A, Khattri S. An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor. Curr Top Med Chem. 2015;15(1):65-72. PubMed PMID: 25579575.
2. Sinha C, Nischal A, Pant KK, Bandaru S, Nayarisseri A, Khattri S. Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition. Bioinformation. 2014 Oct 30;10(10):611-6. doi: 10.6026/97320630010611. eCollection 2014. PubMed PMID: 25489169; PubMed Central PMCID: PMC4248342.
3. Zuo T, Liu D, Lv W, Wang X, Wang J, Lv M, Huang W, Wu J, Zhang H, Jin H, Zhang L, Kong W, Yu X. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J Virol. 2012 May;86(10):5497-507. doi: 10.1128/JVI.06957-11. Epub 2012 Feb 29. PubMed PMID: 22379088; PubMed Central PMCID: PMC3347289.
4. Huang W, Zuo T, Luo X, Jin H, Liu Z, Yang Z, Yu X, Zhang L, Zhang L. Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors. Chem Biol Drug Des. 2013 Jun;81(6):730-41. doi: 10.1111/cbdd.12119. PubMed PMID: 23405965.